FDA Accepts Supplement for FINTEPLA (Fenfluramine) by UCB
The FDA has accepted a supplemental application for FINTEPLA, an epilepsy treatment containing fenfluramine hydrochloride.
Asset / Drug
Drug and asset intelligence for FINTEPLA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.